Search results
Results from the WOW.Com Content Network
The immune-related response criteria, first published in 2009, [1] arose out of observations that immuno-oncology drugs would fail in clinical trials that measured responses using the WHO or RECIST Criteria, because these criteria could not account for the time gap in many patients between initial treatment and the apparent action of the immune ...
The mean response rate for new cancer drugs approved by the U.S. Food and Drug Administration, expressed as relative risk, ranges between 1.38x [3] and 2.37x. [ 4 ] See also
Tumor antigen is an antigenic substance produced in tumor cells, i.e., it triggers an immune response in the host. Tumor antigens are useful tumor markers in identifying tumor cells with diagnostic tests and are potential candidates for use in cancer therapy. The field of cancer immunology studies such topics.
In the escape phase, tumor cells continue to grow and expand in an uncontrolled manner and may eventually lead to malignancies. In the study of cancer immunoediting, knockout mice have been used for experimentation since human testing is not possible. Tumor infiltration by lymphocytes is seen as a reflection of a tumor-related immune response. [5]
Immune cells required for the induction of a cognate/adaptive immune response differ from those cells necessary for the activation of an effector immune response. Although the causes of tissue-specific destruction vary among pathologic states, the effector immune response observed in these conditions is found to converge into one single ...
To create an immune response, a foreign molecule must be present that antibodies can bind to (i.e. the antigen) and cellular damage must exist. Very often, drugs will not be immunogenic because they are too small to induce immune response. However, a drug can cause an immune response if the drug binds a larger molecule.
The immune response to cancer can be categorized into the two main categories as discussed above: innate immunity and adaptive immunity. Innate immunity is the first line of defense against cancer. It consists of non-specific immune cells that can recognize and destroy abnormal cells, including cancer cells.
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology ( immuno-oncology ) and a growing subspecialty of oncology .